Pembrolizumab and olaparib in a cisplatin-refractory testicular cancer patient with a high TMB: first case report.

ABSTRACT: Germ cell tumors (GCTs) represent about 5% of urological cancers affecting mostly younger males with increasing incidence in the last decades. GCTs are very sensitive to cisplatin-based therapy and are highly curable regardless of metastatic stage, likely based on having inherited unique mechanisms of sensitivity to DNA damage and other stressors to prevent germline mutations. Here, we present the first case of a 60-year Caucasian male with a heavily pretreated, cisplatin-refractory extragonadal non-seminomatous GCT (choriocarcinoma) treated with pembrolizumab and olaparib based on high programmed death-ligand 1 expression (tumor proportion score 50% and a combined positive score 55%) high tumor mutational burden, borderline genomic loss of heterozygosity, and a heterozygous variant of unc

SUBMITTER: van Creij NCH 

PROVIDER: S-EPMC11907546 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature